Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
704 (USA) · Dr. Tanaka
consented 2013-10-31
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-08 (study day 39.0); relationship: not assessed
severe
assessed
Severe RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-08 (study day 39.0); relationship: not assessed
Data queries
No data queries.